FAQ: Oncotelic Therapeutics' Deciparticle™ Everolimus Presentations at 2025 San Antonio Breast Cancer Symposium

What is the main announcement from Oncotelic Therapeutics?

Oncotelic Therapeutics announced that three abstracts featuring its investigational intravenous Deciparticle™ everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium.

What is Deciparticle™ everolimus (Sapu003) and how does it work?

Sapu003 is a novel IV formulation of everolimus designed to overcome limitations of oral mTOR inhibitors like Afinitor®, including poor bioavailability and restricted tumor penetration. It was developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea.

When and where will the presentations take place?

The presentations will occur at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9-12, 2025, in San Antonio, Texas.

What type of cancer is Sapu003 being developed to treat?

Sapu003 is being evaluated in an ongoing Phase 1 trial for HR⁺/HER2⁻ metastatic breast cancer.

What information do the accepted abstracts contain?

The abstracts collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial.

Why is this development significant for breast cancer treatment?

This development is significant because Sapu003 addresses limitations of current oral mTOR inhibitors by potentially improving bioavailability and tumor penetration, which could lead to better treatment outcomes for metastatic breast cancer patients.

What is Oncotelic Therapeutics’ focus as a company?

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, particularly for high-unmet-need cancers and rare pediatric indications.

How can investors stay updated on Oncotelic Therapeutics news?

Investors can access the latest news and updates relating to OTLC in the company’s newsroom at https://ibn.fm/OTLC.

What is Oncotelic’s relationship with GMP Bio?

Oncotelic owns 45% of GMP Bio, a joint venture under CEO Dr. Vuong Trieu’s leadership, which is advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics.

Where can I find the full press release about this announcement?

The full press release can be viewed at https://ibn.fm/Ut6V8.